C2CD4D-AS1: A Potential Drug Target and Biomarker (G100132111)

Target Name: C2CD4D-AS1

NCBI ID: G100132111

C2CD4D-AS1

Other Name(s): C2CD4D-AS1 variant 1 | C2CD4D and THEM5 antisense RNA 1, transcript variant 1 | C2CD4D and THEM5 antisense RNA 1

C2CD4D-AS1: A Potential Drug Target and Biomarker

C2CD4D-AS1 is a protein that is expressed in various tissues of the body, including the brain, lungs, heart, and gastrointestinal tract. It is a member of the C2 subfamily of the CD47 family, which is known for its role in hematological malignancies. C2CD4D-AS1 has been shown to be involved in the regulation of cell proliferation, migration, and adhesion, and has been identified as a potential drug target in various diseases.

The C2CD4D-AS1 protein is composed of 216 amino acid residues and has a calculated molecular mass of 23.9 kDa. It is expressed in various tissues of the body, including the brain, lungs, heart, and gastrointestinal tract, and has been shown to be involved in the regulation of cell proliferation, migration, and adhesion.

C2CD4D-AS1 in Cancer

C2CD4D-AS1 has been shown to be involved in the regulation of cell proliferation and has been identified as a potential drug target in various types of cancer. For example, studies have shown that overexpression of C2CD4D-AS1 has been associated with the development of various types of cancer, including lung cancer, breast cancer, and ovarian cancer.

One of the mechanisms by which C2CD4D-AS1 is involved in cancer development is its role in the regulation of cell adhesion. C2CD4D-AS1 has been shown to be involved in the regulation of cell-cell adhesion by interacting with the protein E-cadherin. This interaction between C2CD4D-AS1 and E-cadherin has been shown to contribute to the maintenance of tissue structure and the regulation of cellular behavior.

Another mechanism by which C2CD4D-AS1 is involved in cancer development is its role in cell proliferation. C2CD4D-AS1 has been shown to be involved in the regulation of cell proliferation by interacting with the protein p21 (TIM-3). This interaction between C2CD4D-AS1 and p21 has been shown to contribute to the regulation of cell proliferation and the maintenance of a cancer-promoting state.

C2CD4D-AS1 as a Biomarker

C2CD4D-AS1 has also been identified as a potential biomarker for several types of cancer. For example, studies have shown that C2CD4D-AS1 is expressed in various types of cancer, including lung cancer, breast cancer, and ovarian cancer, and can be used as a biomarker for these diseases.

In addition to its potential as a drug target, C2CD4D-AS1 has also been shown to be involved in the regulation of inflammation and cellular immune response. This suggests that it may have potential as a biomarker for various inflammatory and immune-related diseases.

Conclusion

C2CD4D-AS1 is a protein that is involved in the regulation of cell proliferation, migration, and adhesion, and has been identified as a potential drug target and biomarker in various types of cancer. Further research is needed to fully understand the role of C2CD4D-AS1 in cancer development and its potential as a biomarker.

Protein Name: C2CD4D And THEM5 Antisense RNA 1

The "C2CD4D-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C2CD4D-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets